#Italy #Cancer Treatment #GammaPod #Tema Sinergie #Faenza

GammaPod Revolutionizes Breast Cancer Treatment in Europe

In a significant advancement for cancer care, GammaPod has officially arrived in Europe, marking a new chapter in breast cancer treatment. This innovative technology, known for its precision and effectiveness, was made possible through the dedication of Tema Sinergie SpA, an Italian company based in Faenza. With over four decades of experience in the healthcare sector, Tema Sinergie is committed to pioneering innovative oncology solutions.

The GammaPod system, invented by Professor Cedric Yu from the University of Maryland and manufactured by Xcision Medical Systems, was first installed at the Santa Maria della Misericordia Hospital in Udine, Italy. The introduction of this cutting-edge tool heralds a new era in the way early-stage breast cancer is managed, offering patients hope for more effective treatment.

What is GammaPod?

GammaPod is categorized as Stereotactic Partial Breast Irradiation (S-PBI), a specialized type of Stereotactic Body Radiation Therapy (SBRT). This technique allows oncologists to administer higher doses in fewer treatment sessions compared to conventional radiotherapy methods, which often require multiple fractions over an extended period. The technology aims to optimize the dosimetric advantages of stereotactic radiotherapy specifically for patients seeking breast-conserving treatment.

One of GammaPod's standout features is its ability to provide targeted radiation directly to the tumor, minimizing exposure to surrounding healthy tissues. This is particularly crucial in breast cancer treatment, as it significantly reduces the risk of side effects and collateral damage, thereby enhancing patient quality of life.

Clinical Studies and Results

Recent clinical studies conducted at the Udine hospital further underscore the effectiveness of GammaPod, showcasing its safety and positive impact in pre-operative breast cancer treatment. Results published in the esteemed International Journal of Radiation Oncology, Biology, Physics demonstrate a significant decrease in the proliferation index (Ki-67), which is an essential marker for assessing tumor response to radiotherapy.

Dr. Marco Trovò, head of the radiotherapy department at the Udine hospital, expressed enthusiasm about the results: “GammaPod allows us to deliver a considerable radiation dose in a single session, yielding a clear biological response, as evidenced by the marked reduction in Ki-67 levels.”

This landmark study is a part of a broader initiative to ensure that this advanced technology reaches as many patients as possible. The GammaPod’s capabilities continue to position it as a formidable tool in the fight against early-stage breast cancer.

Upcoming Symposium and International Collaboration

On May 5, 2025, GammaPod will be showcased at the Satellite Symposium entitled “Reducing the Impact of Breast Cancer,” organized by Tema Sinergie during the ESTRO 2025 congress in Vienna. The symposium will feature leading international experts, including Professor Cedric Yu himself, who will discuss the characteristics of this groundbreaking technology. Other presentations will include clinical study outcomes from esteemed colleagues, Dr. Marco Trovò and Professor Asal Rahimi, ensuring a comprehensive exchange of insights and findings.

Tema Sinergie’s commitment to bringing GammaPod to the European market underscores the importance of international collaboration in healthcare innovation. The organization's proactive approach highlights the potential for GammaPod to become an essential component in global breast cancer treatment strategies.

Conclusion

Through innovative technologies like GammaPod, the landscape of breast cancer treatment is rapidly evolving. The introduction of this advanced radiotherapy technique signifies a bright future for patients facing early-stage breast cancer, providing safer, more effective treatment options that promise to enhance their life quality. As Europe embraces this state-of-the-art solution, the fight against breast cancer is poised for significant breakthroughs.

For more information about GammaPod, please visit GammaPod's official site and for insights into the clinical studies, check the International Journal publication00152-X/abstract).

For press inquiries, contact Stefano Camanzi at [email protected].